The use of degradation-resistant GLP-1 analogues (liraglutide in the LEADER trial, and semaglutide in the SUSTAIN-6 trial) in patients with T2DM showed a reduction of cardiovascular mortality, non-fatal acute myocardial infarction (AMI), and stroke compared with the placebo group. This evidence concerns the gene GCG and type 2 diabetes mellitus.